177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Richard P, Baum,; Harshad R, Kulkarni,; Christiane, Schuchardt,; Aviral, Singh,; Martina, Wirtz,; Stefan, Wiessalla,; Margret, Schottelius,; Dirk, Mueller,; Ingo, Klette,; Hans-Jürgen, Wester,

doi:10.2967/jnumed.115.168443

Public

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine • Jul 1, 2016

Authors:

Baum, Richard P

Kulkarni, Harshad R

Schuchardt, Christiane

Abstract

UNLABELLED: The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Fifty-...

Subject

PSMA

radioligand therapy

theranostics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!